RGL-270 is named as an intervention in 2 current clinical trials in our China register. 2 are recruiting patients now. The most common phase is Not applicable. The sponsor with the most trials is Guangdong Association of Clinical Trials (1). The most-studied condition is NSCLC.
| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Study of RGL-270 Single Drug and Combined With Adebelimab in Patients in Patients at High Risk of Recurrence After Radical Treatment of Malignant Solid Tumors
NCT07348042 · ClinicalTrials.gov ↗ · Tumor, Solid
|
Phase 1 | Recruiting | Xian-Jun Yu | China |
|
RGL-270 + ICI in Advanced NSCLC
NCT07652125 · ClinicalTrials.gov ↗ · NSCLC
|
Not applicable | Recruiting | Guangdong Association of Clinical Trials | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Lead sponsor | Trials |
|---|---|
| Guangdong Association of Clinical Trials | 1 |
| Xian-Jun Yu | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 2 | 2 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our China register name RGL-270 as a drug or biological intervention, as of the registry sync on 28 September 2026. Completed and withdrawn studies are not counted.
Yes. 2 of the 2 trials are recruiting: 2 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Guangdong Association of Clinical Trials (1) and Xian-Jun Yu (1). The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how RGL-270 works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how RGL-270 works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists RGL-270 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 28 Sep 2026.